Human Plasminogen activator inhibitor 2(SERPINB2) ELISA kit

Code CSB-EL021070HU
Size 96T,5×96T,10×96T How to order?
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Description

This Human SERPINB2 ELISA Kit was designed for the quantitative measurement of Human SERPINB2 protein in serum, plasma, cell culture supernates, tissue homogenates, cell lysates. It is a Sandwich ELISA kit, its detection range is 15.6 pg/mL-1000 pg/mL and the sensitivity is 3.9 pg/mL.

Target Name serpin peptidase inhibitor, clade B (ovalbumin), member 2
Alternative Names HsT1201 ELISA Kit; Monocyte Arg serpin ELISA Kit; Monocyte Arg-serpin ELISA Kit; Monocyte Arginine-serpin ELISA Kit; Monocyte-derived plasminogen activator inhibitor ELISA Kit; PAI ELISA Kit; PAI-2 ELISA Kit; PAI2 ELISA Kit; PAI2_HUMAN ELISA Kit; Placental plasminogen activator inhibitor ELISA Kit; PLANH2 ELISA Kit; Plasminogen activator inhibitor 2 ELISA Kit; plasminogen activator inhibitor; type 2 ELISA Kit; plasminogen activator inhibitor; type II (arginine-serpin) ELISA Kit; serine (or cysteine) proteinase inhibitor; clade B (ovalbumin); member 2 ELISA Kit; Serpin B2 ELISA Kit; serpin peptidase inhibitor; clade B (ovalbumin); member 2 ELISA Kit; Serpinb2 ELISA Kit; Urokinase inhibitor ELISA Kit
Abbreviation SERPINB2
Uniprot No. P05120
Species Homo sapiens (Human)
Sample Types serum, plasma, cell culture supernates, tissue homogenates, cell lysates
Detection Range 15.6 pg/mL-1000 pg/mL
Sensitivity 3.9 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cell Biology
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human SERPINB2 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
SampleSerum(n=4)
1:200Average %96
Range %90-102
1:400Average %98
Range %93-104
1:800Average %95
Range %89-99
1:1600Average %88
Range %84-92
Recovery
The recovery of human SERPINB2 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9995-103
EDTA plasma (n=4)8682-92
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/mlOD1OD2AverageCorrected
10002.687 2.521 2.604 2.455
5002.126 2.235 2.181 2.032
2501.586 1.573 1.580 1.431
1250.972 0.995 0.984 0.835
62.50.617 0.606 0.612 0.463
31.250.378 0.365 0.372 0.223
15.60.232 0.237 0.235 0.086
00.149 0.148 0.149
ELISA Data Analysis Watch ELISA data processing video & download Curve Expert if needed
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell-derived PAI-1.
Gene References into Functions
  1. miR-15a was identified as a downregulated miRNA in CCFs. Moreover, PAI-2 was identified as a novel target gene of miR-15a. PMID: 29347950
  2. Single nucleotide polymorphisms in ICAM1 (rs1799969) and SERPINB2 (rs6103) genes were found to be protective against thalidomide-induced peripheral neuropathy (TiPN). In children with inflammatory bowel disease, TiPN is common but mild and generally reversible. Cumulative dose seems to be the most relevant risk factor, whereas polymorphisms in genes involved in neuronal inflammation may be protective. PMID: 28817461
  3. serpinB2 bound to and stabilized p21 to mediate senescence in a proteasome-independent manner, indicating that serpinB2 has a direct role in senescence. Thus, this study reveals a unique mechanism by which serpinB2 maintains senescence through stabilization of p21 protein levels. PMID: 28794016
  4. findings demonstrate the prospective role of SerpinB2 as a novel biomarker for acquired gefitinib resistance and a potential target for non-small cell lung cancer treatment. PMID: 27558531
  5. SerpinB2 promotes miR-200c/141 cluster overexpression-induced breast cancer cell metastasis PMID: 28427146
  6. PAI-2 likely plays a key role in cardiovascular disease through multiple pathophysiologic processes including racial dependency, platelet clot initiation and propagation, oxidative stress, inflammation effects on HDL metabolism and coagulation PMID: 27174532
  7. This study is the first to associate enhancer RNAs with SERPINB2 and is the first demonstration of acquisition of NELF binding by enhancer RNAs on chromatin. PMID: 28578223
  8. This study establishes a novel role for SerpinB2 in the stromal compartment in pancreatic ductal adenocarcinoma invasion through regulation of stromal remodelling PMID: 28346421
  9. The variant of PAI-2 gene was associated with coronary artery disease and recurrent coronary event risk in Chinese Han population, in Xinjiang. PMID: 26573152
  10. SerpinB2 plays an important role in proteostas PMID: 26083412
  11. Polymorphisms in this fibrinolytic system gene are associated with recurrent spontaneous abortion in Sinhalese women, probably through impaired implantation. PMID: 25444509
  12. PAI-2 was up-regulated in tensioned keloid fibroblasts and normal fibroblasts, but more so in keloid cells. Knockdown of PAI2 reduced cell proliferation in fibroblasts under tension. PMID: 25046655
  13. Soluble guanylate cyclase activators might alleviate or reverse vascular remodeling in pulmonary hypertension through the up-regulation of PAI-2. PMID: 25704756
  14. We found no association between allele frequency and risk of multiples sclerosis for any single nucleotide polymorphism investigated for serpinb2 PMID: 23897640
  15. A role for SERPINB2 in patients with head and neck squamous cell carcinoma. PMID: 23661500
  16. Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels. PMID: 23874812
  17. PSMB1 is part of the transcriptional machinery required for gastrin stimulated expression of PAI-2 and Reg1. PMID: 23544109
  18. SerpinB2 can be induced by lentiviral infection in vivo. PMID: 23460840
  19. Low expression of PAI-2 serves as a novel marker of portal vein tumor embolism and poor prognosis for hepatocellular cancer. PMID: 23188538
  20. Increased expression of SerpinB2 by an inflammatory stimulus is sufficient to generate structures that resemble secretory vesicles. PMID: 23474086
  21. PAI-2 expression may be negatively associated with the invasive potential of hepatocellular carcinoma (HCC). PMID: 23527801
  22. a model for the transcriptional control of the human PAI-2 gene PMID: 22334683
  23. Data suggests that PAI-2, in endothelial cells induced with inflammatory stimuli, can inhibit proteasome and thus tilt the balance favoring proapoptotic signaling. PMID: 21976669
  24. High PAI-2 expression is associated with poor treatment response in colorectal carcinoma. PMID: 21744990
  25. Plasminogen activator inhibitor-2 (PAI-2) secreted from activated mast cells induces alpha-smooth muscle actin (alpha-SMA) expression in dermal fibroblasts PMID: 21477997
  26. Our results suggest that P. intermedia may contribute to periodontal tissue destruction by upregulating tPA and PAI-2 expression in hPDL cells via multiple signaling pathways. PMID: 21314733
  27. The decrease in plasma PAI-2 observed in preeclampsia does not precede the clinical onset of the disease. PMID: 20205627
  28. Results describe periodontal treatment effects on gingival crevicular fluid (GCF) interleukin-6 (IL-6), tissue-type plasminogen activator (tPA), plasminogen activator inhibitor-2 (PAI-2), albumin levels in type 2 diabetic patients. PMID: 20845058
  29. HPV-transformed CaSki cells express high levels of SerpinB2, with cellular distribution, glycosylation, secretion, cleavage, induction and urokinase binding similar to that for primary cells; SerpinB2 efficiently binds the proteasomal subunit member beta1 PMID: 20974129
  30. PAI-2 has a role in promoting the differentiation of human epidermal keratinocytes. PMID: 20494554
  31. It is feasible to detect fetal trisomy 18 non-invasively by maternal plasma SERPINB2 RNA-SNP analysis provided that sufficient quantities of plasma samples are used. PMID: 19650060
  32. regulator of monocyte proliferation and differentiation PMID: 11929770
  33. plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas PMID: 11949838
  34. Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene PMID: 12105855
  35. post-transcriptional regulation of the PAI-2 gene is modulated by tristetrapolin PMID: 12578825
  36. Data suggest that the CD-loop functions as a redox-sensitive switch that converts plasminogen activator inhibitor type 2 (PAI-2) between an active stable monomeric and a polymerogenic conformation. PMID: 12682008
  37. These results indicate that PAI-2 may enhance Rb's tumor suppressor activity and suggest a potential therapeutic role for PAI-2 against HPV-transformed lesions. PMID: 12944478
  38. evidence that a polymorphism of the PAI-2 gene is associated with an increased risk of myocardial infarction PMID: 14653443
  39. PAI-2 has a role in scleroderma, as seen by its expression in fibroblasts PMID: 15500643
  40. PAI-2 expression has a potent suppressive effect on human papillomavirus type 18 oncogene transcription mediated by Rb and LIP, a finding with potential implications for prognosis and treatment of human papillomavirus-transformed lesions. PMID: 15767426
  41. PAI2 is present in normal conjunctiva. PMID: 15887231
  42. investigated the unique mousetrap inhibition mechanism of serpins through saturation mutagenesis of the P8 residue for PAI-2 PMID: 16214170
  43. the urokinase/PAI-2 complex is a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein PMID: 16459332
  44. SerpinB2 is a potentially important inducible host factor that significantly promotes HIV-1 replication PMID: 16923810
  45. in patients with complex congenital malformations amniotic fluid levels of plasminogen activator inhibitor type 2(PAI2) PMID: 17141398
  46. Data indicate that this family did not follow the Mendelian inheritance pattern; the Ser(413)/Ser genotype in 60% of the affected members might increase the risk for autoimmune syndromes such as anti-phospholipid syndrome or systemic lupus erythematosus. PMID: 17657675
  47. PAI-2 is able to inhibit and clear urokinase plasminogen activator activity without initiating mitogenic signalling events through the very-low-density-lipoprotein receptor (VLDLr). PMID: 17696882
  48. Type 2 diabetes in this study seems not to increase gingival crevicular fluid levels of the evaluated inflammatory mediators PAI2. PMID: 18472001
  49. SerpinB2 is a cell survival factor that modulates Rb repression of proapoptotic signal transduction PMID: 18632617
  50. PAI-2 can inhibit cell-bound tPA activity in vitro and thus prevent plasmin formation PMID: 18690354

Show More

Hide All

Subcellular Location Cytoplasm. Secreted, extracellular space.
Protein Families Serpin family, Ov-serpin subfamily
Database Links

HGNC: 8584

OMIM: 173390

KEGG: hsa:5055

STRING: 9606.ENSP00000299502

UniGene: Hs.594481

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
Address
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1